Goldman Sachs
SLN

Goldman Sachs’s Silence Therapeutics SLN Stock Holding History

Goldman Sachs’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
155,929
+103,418
+197% +$728K ﹤0.01% 4806
2026
Q1 		$277K Buy
52,511
+34,397
+190% +$189K ﹤0.01% 5935
2025
Q4 		$110K Sell
18,114
-4,530
-20% -$29K ﹤0.01% 6175
2025
Q3 		$118K Buy
+22,644
New +$126K ﹤0.01% 6058
2025
Q2 		– Sell
-24,375
Closed -$68.7K – 6389
2025
Q1 		$68.7K Sell
24,375
-12,510
-34% -$61.1K ﹤0.01% 5843
2024
Q4 		$254K Buy
36,885
+6,253
+20% +$80.7K ﹤0.01% 5554
2024
Q3 		$557K Buy
30,632
+14,376
+88% +$267K ﹤0.01% 4988
2024
Q2 		$309K Sell
16,256
-5,483
-25% -$117K ﹤0.01% 5090
2024
Q1 		$470K Buy
+21,739
New +$473K ﹤0.01% 4775
2023
Q4 		– Sell
-266,667
Closed -$2.62M – 5820
2023
Q3 		$2.62M Sell
266,667
-143,333
-35% -$1.06M ﹤0.01% 3548
2023
Q2 		$2.25M Sell
410,000
-250,000
-38% -$1.51M ﹤0.01% 3788
2023
Q1 		$4.09M Sell
660,000
-189
-0% -$2.23K ﹤0.01% 3229
2022
Q4 		$10.1M Buy
660,189
+189
+0% +$2.48K ﹤0.01% 2583
2022
Q3 		$6.62M Hold
660,000
– – ﹤0.01% 2889
2022
Q2 		$7.82M Sell
660,000
-305,815
-32% -$3.72M ﹤0.01% 2733
2022
Q1 		$18.4M Buy
965,815
+205,815
+27% +$4.1M ﹤0.01% 2121
2021
Q4 		$18.2M Buy
+760,000
New +$17.6M ﹤0.01% 2201

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs's SLN Position: Q2 2026 in Review

Goldman Sachs increased its Silence Therapeutics (SLN) stake by 197% in Q2 2026, buying an estimated $728K and bringing the position to 155,929 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4806.

Goldman Sachs first reported a position in SLN in Q4 2021 and has held it in 17 quarters since. The position peaked at $18.4M in Q1 2022. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Goldman Sachs held 155,929 shares of Silence Therapeutics worth $1.71M as of Q2 2026.
  • Goldman Sachs bought 103,418 Silence Therapeutics shares in Q2 2026, an estimated $728K.
  • Silence Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4806 holding.
  • Goldman Sachs first reported a position in Silence Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Goldman Sachs's Silence Therapeutics position peaked at $18.4M in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.